Medicus Pharma Submits Modification Application Through European Union Clinical Trials Information System For Its Phase 2b Trial Of Teverelix In Advanced Prostate Cancer

Loading news article.

Medicus Pharma Submits Modification Application Through European Union Clinical Trials Information System For Its Phase 2b Trial Of Teverelix In Advanced Prostate Cancer | WAPE

Medicus Pharma Submits Modification Application Through European Union Clinical Trials Information System For Its Phase 2b Trial Of Teverelix In Advanced Prostate Cancer

Article summary

Related companies

Comments —